Skip to main content

Eloxx Pharmaceuticals, Inc.

corporate_fare Company Profile

Eloxx Pharmaceuticals, Inc.

ELOX·NASDAQ·Life Sciences·CIK 0001035354

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops new, small molecule drug candidates. These candidates are designed to modify the ribosome and encourage the ribosome to "read through" premature stop codons caused by nonsense mutations, allowing for the production of full-length proteins. This approach of targeting ribosome subunits offers a way to treat various genetic diseases. Nonsense mutations are responsible for approximately 10% to 12% of patients with a specific genetic disease. There are over 7,000 inherited genetic diseases affecting 350 million people globally. The company's immediate priority is to advance the clinical development of its main product candidate, exaluren, for rare kidney diseases. Additionally, through a collaboration with Almirall, S.A., it is developing ZKN-013 for rare skin diseases. Exaluren is a new eukaryotic ribosome-selective glycoside (ERSG) candidate designed to induce premature termination codon (PTC) readthrough in the presence of nonsense mutations, aiming to restore full-length proteins. Eloxx Pharmaceuticals believes this mechanism could be applicable to all genetic diseases caused by nonsense mutations. Initially, exaluren is being developed to induce full-length Collagen IV protein for the treatment of Alport syndrome with nonsense mutations (NMAS). NMAS is a genetic kidney disorder, a subset of Alport syndrome, caused by the loss of one of three Collagen IV subtypes: Collagen IV alpha 3 (COL4A3), alpha 4 (COL4A4), or alpha 5 (COL4A5), leading to the loss of the Collagen IV alpha 3,4,5 trimer. This trimer is produced in podocyte cells and is essential for the kidney's filtration structure, which includes the glomerular basement membrane (GBM), foot processes (FPs), and slit diaphragms. Eloxx Pharmaceuticals estimates that NMAS affects approximately 6% to 7% of Alport syndrome patients, or about 5,000 patients in the United States and approximately 14,000 patients in developed countries and China. NMAS is characterized by blood (hematuria) and protein (proteinuria) in the patient's urine, leading to progressive kidney disease, hearing loss, and eye abnormalities.

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for ELOX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ELOX spans 8-K, 10-Q, 4, S-1/A.

Recent high-impact activity:

  • Eloxx Posts Smaller-Than-Expected Q3 Loss of 49 Cents a Share
  • FDA Clears Eloxx IND for Exaluren in ADPKD; First Dosing Set for 3Q 2027
  • Eloxx Posts $4.5M Q2 Loss, $62M Cash; Phase 2b Alport Trial Set for Q3
  • Eloxx Q2 Loss Widens to $4.5M; Cash Runway Extended to Mid-2028 After $66M Raise
  • Eloxx Posts $8.3M Net Loss, Flags Material Weakness; Cash Runway Extended Through June 2027

Short Interest & Short Volume

2.07 days to cover

FINRA reported short interest of 52,603 shares in ELOX as of the October 30, 2026 settlement, a 27.2% increase from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 47.0% of ELOX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)52,603 shares as of October 30, 2026
Change vs prior period▲ 27.2%
Days to cover2.07 at avg daily volume of 25,378
Daily short volume (FINRA facilities)47.0% of 2,341 shares on November 20, 2026
5-day average short volume53.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ELOX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-01.

1 shelf registrationreverse split

Critical Capital Raise Announced · Premium Offering Price

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →
$10.69
52-week range · as of 2026-08-11 $0.0231 – $19.96
Market cap
$43.69M
Volume
15K (0.6× avg)
3-mo avg 24.4K
Live data · 2026-11-22 12:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ELOX - Latest Insights

ELOX
Nov 16, 2026, 9:32 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $13.15
Real-time Price: $10.69 info
Change: -$2.46 (-19%) info
Market Cap: $43.687M info
ELOX
Oct 29, 2026, 8:34 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $13.32
Real-time Price: $10.69 info
Change: -$2.63 (-20%) info
Market Cap: $43.687M info
ELOX
Aug 12, 2026, 6:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $19.18
Real-time Price: $10.69 info
Change: -$8.49 (-44%) info
Market Cap: $43.687M info
ELOX
Aug 11, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.18
Real-time Price: $10.69 info
Change: -$8.49 (-44%) info
Market Cap: $43.687M info
ELOX
Aug 11, 2026, 5:02 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $19.18
Real-time Price: $10.69 info
Change: -$8.49 (-44%) info
Market Cap: $43.687M info
ELOX
Jun 17, 2026, 5:15 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $12.00
Real-time Price: $10.69 info
Change: -$1.31 (-11%) info
Market Cap: $43.687M info
ELOX
Jun 04, 2026, 5:17 PM EDT
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $0.370
Real-time Price: $10.69 info
Change: +$10.32 (+2,789%) info
Market Cap: $43.687M info
ELOX
Jun 01, 2026, 4:55 PM EDT
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $0.370
Real-time Price: $10.69 info
Change: Reverse Stock Split info
Market Cap: $43.687M info
ELOX
Jun 01, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.370
Real-time Price: $10.69 info
Change: Reverse Stock Split info
Market Cap: $43.687M info
ELOX
May 08, 2026, 4:27 PM EDT
Filing Type: DEF 14C
Importance Score:
9
Price at Filing: $0.1301
Real-time Price: $10.69 info
Change: Reverse Stock Split info
Market Cap: $43.687M info
ELOX
May 07, 2026, 5:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.1301
Real-time Price: $10.69 info
Change: Reverse Stock Split info
Market Cap: $43.687M info
ELOX
May 07, 2026, 4:57 PM EDT
Filing Type: S-1
Importance Score:
9
Price at Filing: $0.1301
Real-time Price: $10.69 info
Change: Reverse Stock Split info
Market Cap: $43.687M info
ELOX
May 05, 2026, 6:11 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.1799
Real-time Price: $10.69 info
Change: Reverse Stock Split info
Market Cap: $43.687M info
ELOX
May 01, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.190
Real-time Price: $10.69 info
Change: Reverse Stock Split info
Market Cap: $43.687M info
ELOX
Apr 28, 2026, 5:24 PM EDT
Filing Type: PRE 14C
Importance Score:
9
Price at Filing: $0.120
Real-time Price: $10.69 info
Change: Reverse Stock Split info
Market Cap: $43.687M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets